Through network pharmacology analysis and in vivo experimental validation, we demonstrated for the first time that SKP may alleviate ferroptosis by inhibiting HIF-1α/HO-1 signaling, leading to a reduction in kidney damage, which is one of the mechanisms of SKP in the treatment of DKD. Here, HMOX1 is linked to diabetic kidney disease.